Ritivel
AI-native platform for Life-Sciences Documentation
Winter 2026ActiveHealthcareHealthcare ITGenerative AIComplianceEnterprise SoftwareRegtechBiotechnologySan Francisco, CA, USA
Company
https://www.ritivel.comRitivel is an AI-native workspace for regulatory and medical writing teams at life sciences companies. Our AI agents draft CTDs, CSRs, INDs, and BLAs in minutes instead of weeks, helping drugs reach patients faster.
Every month a drug is delayed from reaching the market costs pharma companies ~$45M in lost revenue and more importantly, delays treatment for thousands of patients who need it. Yet regulatory teams are stuck in a painful, months-long process: synthesizing thousands of pages of clinical data, hunting through SharePoint folders for the right documents, chasing colleagues for missing inputs, and manually drafting submissions.
Ritivel deploys AI agents that transform how regulatory teams work. Our agents generate comprehensive first drafts directly in Microsoft Word, following FDA formatting requirements and pulling from your existing clinical data and prior submissions. Every data point includes citations linked back to the original source, so reviewers can verify with one click. Connected to SharePoint and Veeva, our agents automatically source the right documents. Integrated with Outlook, they handle reminder emails and follow-ups automatically.
We're engineers who previously built AI copilots at Microsoft Research. After 50+ conversations with pharma professionals, we discovered the critical bottleneck in regulatory submissions and built Ritivel to solve it.
Verdict
High Signal
Market Opportunity
Regulatory submissions in life sciences is a genuine enterprise pain point with quantifiable cost — $45M/month per delayed drug is a real industry figure. ICP is clear: regulatory affairs and medical writing teams at pharma/biotech companies. The regulatory documentation software market is multi-billion and sticky; customers like Veeva and PAREXEL dominate adjacent spaces, validating willingness to pay at enterprise scale.
Medium Signal
Founder Signal
CEO Pavan Kalyan has the strongest profile: Research Fellow at Microsoft (Jul 2024–Jul 2025), published at NeurIPS, ACL, EACL, IIT Bombay Btech+Mtech in EE/AI — legitimate deep ML credentials. CTO Nirmit Arora also a Microsoft Research Fellow (Jul 2024–Oct 2025), IIT Dharwad CS grad with ML background. Both are young (likely 2022–2024 grads) with ~1 year each at Microsoft Research — real but not senior. CBO Gunin Gupta is non-technical: Kearney consultant (Oct 2023–Jul 2025) and Slice ops associate — brings pharma/business context but no engineering depth. Team is technically credible for the AI work but very early-career with no prior exits.
Medium Signal
Competition
The regulatory tech space has established players — Veeva Vault for document management, PAREXEL and Certara for regulatory consulting/software, and newer AI entrants like Unlearn.ai and various LLM wrappers targeting pharma. Ritivel's differentiators (Word-native output, citation traceability, SharePoint/Veeva connectors, local-first deployment) are meaningful but not yet proven defensible moats. No proprietary data advantage is cited, and big consulting firms like PAREXEL could add similar AI features.
Medium Signal
Product
The product concept is well-articulated — AI agents drafting CTDs, CSRs, INDs, BLAs with citations, SharePoint/Veeva integration, Word output. However, there are no named customer logos, revenue figures, or usage metrics cited anywhere. The description mentions 50+ customer discovery conversations but no paying pilots or contracts are referenced. This is a credible MVP story but still pre-traction as far as the data shows.
OverallB Tier
Ritivel targets a real, painful, and expensive enterprise problem with a technically credible team that has genuine ML research pedigree from Microsoft Research. However, this is an early-stage team — all three founders are effectively fresh grads with ~1 year of post-college work experience each, no prior exits, and no demonstrated customer traction in the data provided. The non-technical CBO (Kearney consulting) adds domain framing but the team lacks regulatory industry insiders or pharma-side operators. The competitive landscape is real: Veeva owns document management in pharma and could expand, while multiple AI-native regulatory startups are emerging simultaneously. The core risk is whether a team this early-career can navigate enterprise pharma sales cycles and build the trust required for regulated submission workflows.
Active Founders
